A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
| Autor: | Park, S., Lee, M.-H., Seong, M., Kim, S.T., Kang, J.-H., Cho, B.C., Lee, K.H., Cho, E.K., Sun, J.-M., Lee, S.-H., Ahn, J.S., Park, K., Ahn, M.-J. |
|---|---|
| Zdroj: | In Annals of Oncology October 2020 31(10):1397-1404 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|